1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Drugs In Development, 2022, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 8, 5, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 4, 2, 2, 3 and 1 molecules, respectively.
Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Poliomyelitis - Overview
- Poliomyelitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Poliomyelitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Poliomyelitis - Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co Ltd
- Beijing Tiantan Biological Products Co Ltd
- Bharat Biotech Ltd
- Biken Co Ltd
- Biological E Ltd
- Biological Mimetics Inc
- Boryung Pharmaceutical Co Ltd
- CanSino Biologics Inc
- Grifols SA
- Helix Biogen Institute
- Intravacc BV
- Johnson & Johnson
- KM Biologics Co Ltd
- LG Chem Ltd
- Micron Biomedical Inc
- Nanolek
- Panacea Biotec Ltd
- Serum Institute of India Pvt Ltd
- Shantha Biotechnics Pvt Ltd
- Statera Biopharma Inc
- Vaxxas Inc
- Wuhan Institute of Biological Products Co Ltd
- Poliomyelitis - Drug Profiles
- Product Description
- Mechanism Of Action
- Product Description
- Mechanism Of Action
- Product Description
- Mechanism Of Action
- Product Description
- Mechanism Of Action
- Product Description
- Mechanism Of Action
- Product Description
- Mechanism Of Action
- Product Description
- Mechanism Of Action
- BK-1310 - Drug Profile
- Product Description
- Mechanism Of Action
- CSB-017 - Drug Profile
- Product Description
- Mechanism Of Action
- immune globulin (human) - Drug Profile
- Product Description
- Mechanism Of Action
- JNJ-2348 - Drug Profile
- Product Description
- Mechanism Of Action
- KD-2396 - Drug Profile
- Product Description
- Mechanism Of Action
- KD-370 - Drug Profile
- Product Description
- Mechanism Of Action
- LBVC - Drug Profile
- Product Description
- Mechanism Of Action
- LBVD - Drug Profile
- Product Description
- Mechanism Of Action
- polio (trivalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio [serotype 1] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio [serotype 2] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio [serotype 2] vaccine 1 - Drug Profile
- Product Description
- Mechanism Of Action
- polio [serotype 3] (monovalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio [serotype 3] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio [serotype 3] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio [serotypes 1, 2, 3] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio [strain Sabin] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio [strain Sabin] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio [strain Sabin] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio [strain Sabin] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- polio vaccine 2 - Drug Profile
- Product Description
- Mechanism Of Action
- poliomyelitis (trivalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- poliomyelitis [sabin] (vero cell) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- poliomyelitis [serotype PV3] (virus like particles) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- poliomyelitis vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- poliomyelitis vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- poliomyelitis vaccine + rotavirus vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- SA-702 - Drug Profile
- Product Description
- Mechanism Of Action
- Poliomyelitis - Dormant Projects
- Poliomyelitis - Discontinued Products
- Poliomyelitis - Product Development Milestones
- Featured News & Press Releases
- Jun 09, 2022: Sinovac Biotech receives WHO prequalification for polio vaccine
- Apr 12, 2022: Pertussis, Diphtheria, Tetanus, Polio, Hib vaccine filed in Japan: BIKEN/Mitsubishi
- Apr 11, 2022: Notification of manufacturing and marketing approval application for pertussis/diphtheria/tetanus/inactivated polio/Hib combined vaccine (BK1310/MT-2355)
- Apr 11, 2022: Marketing authorization application of pertussis, diphtheria, tetanus, inactivated polio and Hib combined vaccine (BK1310/MT-2355)
- Jul 20, 2021: Intravacc's inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China
- Dec 09, 2020: New polio vaccine against strain that threatens eradication is safe and generates immune response in adults, young children, and infants
- Apr 23, 2020: AJ Vaccines secures WHO Prequalification for polio vaccine Picovax
- Apr 16, 2019: Sinovac announces positive results from Phase III trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) published in the journal of Infectiou
- Mar 11, 2019: LG Chem gets $33.4 mil. from Gates Foundation for vaccine development
- May 21, 2018: A single-injection vaccine for the polio virus
- Apr 19, 2018: Sinovac Announces Preliminary Results of Phase III Trial on sIPV
- Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate
- Sep 16, 2014: Vaxxas initiates research project on advancing next generation technology for polio vaccine delivery
- Oct 31, 2012: Statens Serum Institut receives a grant of $158,739 from Bill & Melinda Gates Foundation
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Poliomyelitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
- Poliomyelitis - Pipeline by Beijing Tiantan Biological Products Co Ltd, 2022
- Poliomyelitis - Pipeline by Bharat Biotech Ltd, 2022
- Poliomyelitis - Pipeline by Biken Co Ltd, 2022
- Poliomyelitis - Pipeline by Biological E Ltd, 2022
- Poliomyelitis - Pipeline by Biological Mimetics Inc, 2022
- Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, 2022
- Poliomyelitis - Pipeline by CanSino Biologics Inc, 2022
- Poliomyelitis - Pipeline by Grifols SA, 2022
- Poliomyelitis - Pipeline by Helix Biogen Institute, 2022
- Poliomyelitis - Pipeline by Intravacc BV, 2022
- Poliomyelitis - Pipeline by Johnson & Johnson, 2022
- Poliomyelitis - Pipeline by KM Biologics Co Ltd, 2022
- Poliomyelitis - Pipeline by LG Chem Ltd, 2022
- Poliomyelitis - Pipeline by Micron Biomedical Inc, 2022
- Poliomyelitis - Pipeline by Nanolek, 2022
- Poliomyelitis - Pipeline by Panacea Biotec Ltd, 2022
- Poliomyelitis - Pipeline by Serum Institute of India Pvt Ltd, 2022
- Poliomyelitis - Pipeline by Shantha Biotechnics Pvt Ltd, 2022
- Poliomyelitis - Pipeline by Statera Biopharma Inc, 2022
- Poliomyelitis - Pipeline by Vaxxas Inc, 2022
- Poliomyelitis - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2022
- Poliomyelitis - Dormant Projects, 2022
- Poliomyelitis - Discontinued Products, 2022
- Number of Products under Development for Poliomyelitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Beijing Minhai Biotechnology Co Ltd
- Beijing Tiantan Biological Products Co Ltd
- Bharat Biotech Ltd
- Biken Co Ltd
- Biological E Ltd
- Biological Mimetics Inc
- Boryung Pharmaceutical Co Ltd
- CanSino Biologics Inc
- Grifols SA
- Helix Biogen Institute
- Intravacc BV
- Johnson & Johnson
- KM Biologics Co Ltd
- LG Chem Ltd
- Micron Biomedical Inc
- Nanolek
- Panacea Biotec Ltd
- Serum Institute of India Pvt Ltd
- Shantha Biotechnics Pvt Ltd
- Statera Biopharma Inc
- Vaxxas Inc
- Wuhan Institute of Biological Products Co Ltd
